| Mr Francis George, | |
|
66 High Ridge Dr, Cumberland, RI 02864-3908 | |
| (401) 333-6155 | |
| Not Available |
| Full Name | Mr Francis George |
|---|---|
| Gender | Male |
| Speciality | Physical Therapist |
| Location | 66 High Ridge Dr, Cumberland, Rhode Island |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164843058 | NPI | - | NPPES |
| 7564-2 | Other | RI | BLUE CROSS BLUE SHIELD OF RHODE ISLAND |
| Mailing Address | Practice Location Address |
|---|---|
| Mr Francis George, 66 High Ridge Dr, Cumberland, RI 02864-3908 Ph: (401) 333-6155 | Mr Francis George, 66 High Ridge Dr, Cumberland, RI 02864-3908 Ph: (401) 333-6155 |
News Archive
In cells, DNA is first converted to RNA, and RNA is next converted to proteins-a complicated process involving several other steps. Nonsense-mediated RNA decay is a processing pathway in cells that, like a broom, cleans up erroneous RNA to prevent its productive conversion into an aberrant protein, which could lead to disease.
Isis Pharmaceuticals, Inc. announced the initiation of a Phase 1 study of ISIS-FXIRx, an antisense drug designed to treat clotting disorders. ISIS-FXIRx inhibits the production of Factor XI, a clotting factor that is an important component of the coagulation pathway. Because of its role in the intrinsic coagulation pathway, inhibition of Factor XI could offer an effective approach for preventing the formation of blood clots with a lower risk of bleeding.
Progenics Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA), along with the European Medicines Agency (EMA) of the European Union (E.U.) and Health Canada, the Canadian Regulatory Agency, have each approved single-use, pre-filled syringes of RELISTOR® (methylnaltrexone bromide) Subcutaneous Injection for use in their respective territories. These pre-filled syringes provide a simplified dosing option for the treatment of opioid-induced constipation (OIC) in palliative-care patients with advanced illness.
InteKrin Therapeutics Inc. announced today it will present 6 month Phase 2b clinical data for edema in diabetic patients showing differentiation for INT131, a Selective PPAR-gamma Modulator (SPPARM), from Actos® pioglitazone, at the American Diabetes Association annual meeting in Orlando, FL, Monday, June 28, 2010 at 2:45 pm EDT during the "Update on BARI 2D -Treatment of Insulin Resistance" session.
› Verified 4 days ago
Mr. Michael Dudley Shaw, MPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 2138 Mendon Rd, #302, Cumberland, RI 02864 Phone: 401-334-0218 Fax: 401-334-9531 | |
Lepre Pt Of Cumberland Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 2295 Diamond Hill Rd, Cumberland, RI 02864 Phone: 401-333-9787 Fax: 401-333-9785 | |
Bizzy Bees Therapy Llc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 30 Martin St Unit 4-3, Cumberland, RI 02864 Phone: 401-225-7728 Fax: 401-644-6141 | |
Tina Deroy, P.T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 100 Chambers Street, Cumberland, RI 02864 Phone: 401-724-7500 | |
Karen M. Sullivan, P.T. Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 2295 Diamond Hill Rd, Cumberland, RI 02864 Phone: 401-333-9787 Fax: 401-333-9785 | |
Cynthia Carter, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 100 Chambers St, Cumberland, RI 02864 Phone: 401-724-7500 |